# GMZ2-Aluminum Hydroxide Phase I, Tübingen

> **NCT00397449** · PHASE1 · UNKNOWN · sponsor: **European Vaccine Initiative** · enrollment: 30 (estimated)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)

## Key facts

- **NCT ID:** NCT00397449
- **Lead sponsor:** European Vaccine Initiative
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2007-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397449, "GMZ2-Aluminum Hydroxide Phase I, Tübingen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00397449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*